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Dear Readers 
With the recent advancements in diagnostics, the 
diagnostic field is now moving from one analysis 
to identify one disorder to one analysis identifying 
multiple disorders. This has become possible with the 
Omics and informatics based clinical diagnostics in 
the area of Precision Medicine. These technologies 
have tremendous application in research and 
therapeutics as well. As these are gaining momentum, 
people are becoming more interested in personalized 
and preventive medicine. Correspondingly, along with 
it the use of Artificial intelligence, mobile healthy 
and digital pathology is revolutionizing the world of 
diagnostics. This Labrad is in line with this year’s 
Pathology Research Day theme ‘Omics, Artificial 
intelligence and Digitalization in Diagnostics’.  The 
3rd Pathology Research Day was conducted on 
October 15th 2021.
A compilation of articles covering the application 
of various Omics, Artificial Intelligence based 
technologies and digital Pathology in improving the 
diagnostics. We have some interesting discussions 
like challenges and solutions for implementing digital 
pathology in resource limited setting, applications of 
artificial intelligence in diagnostics, metabolomics 
and genomics in identification of different disorders. 
We value your opinion and feedback regarding 
topic selections, educational and resource materials, 




From the Editor’s Desk
The day to day progress of clinical laboratories 
will be dreadfully impacted by two disruptive 
technologies: Machine learning and artificial 
intelligence. Artificial intelligence and machine 
learning software are beginning to integrate 
themselves as tools for efficiency and accuracy within 
pathology laboratories. Artificial intelligence (AI) 
represents a valuable tool used to improve diagnostics 
through more accurate detection of pathology, better 
laboratory workflows, improved decision support, and 
reduced costs, leading to higher efficiencies. 
For clinical laboratories, timely and precise specimen 
labelling is expected to ensure correct patient 
identification from collection to results reporting. 
Barcoding is a system of using varying width bars 
as a way to provide identification information. Its 
purpose is to ensure accurate sample identification 
and accession. It is an optical machine-readable 
representation of data, which shows certain data 
on certain products in the laboratory. Electronic 
identification such as two-dimensional barcodes 
can certainly include two or more person-specific 
identifiers to comply with this requirement. 
Types of Barcoding: There are many types 
of barcodes, the most common ones being one 
dimensional and two dimensional. 
Single Dimensional Barcode: In a single-
dimensional barcode, the vertical lines and their 
spacing constitute the code, but the whole length 
of the vertical lines are not essential for the codes. 
It is said that the code is repeated in perpendicular 
Role of Barcoding in a Clinical Laboratory to 
Reduce Pre-Analytical Errors
Iffat Arman
Clinical Chemistry   
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directions, so a symbol along with printing defects, 
such as spots or voids, can still be read. 
Two Dimensional Barcode: Two-dimensional 
barcodes seek information along with the height as 
well as the length of the symbol. As a result of that 
construction, these barcodes have greater storage than 
the one-dimensional barcode. A two-dimensional 
barcode is not comprised of bars or lines but rather 
of black-and-white cells arranged in a matrix pattern 
(often laid out in a square). This square image is 
usually simpler to scan than linear barcodes, which 
fits better on curved surfaces like test tubes or patient 
wristbands. 
Barcodes provide patient tracking and sample 
management. Besides laboratory samples, barcodes 
used on calibrators and blood products, reagents/ 
kits, quality controls in a clinical laboratory. Bar-
coding acts as an artificial intelligence tool that 
helps record retrieval and is safer for patients in 
terms of anonymity, accuracy, and elimination 
of human error. Bar-coding the specimen label 
effectively reduces clerical errors, minimises 
mistakes in patient specimen handling, and increases 
productivity.
Case presentation: A 11-year-old boy presented with 
pallor and jaundice and had a history of regular 
blood transfusions for two years. Family history was 
unremarkable. Full blood count showed hemoglobin 
(Hb): 8 g/dL, white blood cells: 2.7 X 109/L, platelets 
96 X 109/L and reticulocyte count of 1.5 percent. The 
direct antiglobulin test was negative. Liver functions 
tests revealed normal enzyme with high total (2 mg/
dl) and unconjugated bilirubin (1.4mg/dl). Serum 
ferritin was high (6561 ng/ml), while viral profile 
including HIV, hepatitis B and C were negative. 
Peripheral blood film revealed anisopoikilocytosis, 
elliptical cells, polychromasia, basophilic stippling, 
fragmented red cells, nucleated red cells, myelocytes 
and metamyelocytes (figure 1). Hemoglobin variant 
study by high performance liquid chromatography 
showed normal composition Hb A (96 percent) and 
Hb A2 (3.3 percent). Bone marrow aspiration and 
trephine exhibited erythroid hyperplasia with marked 
dysplastic changes including bi- and multinucleated 
erythroid precursors, nuclear to cytoplasmic 
asynchrony, inter-cytoplasmic and intra-nuclear 
bridging, and   nuclear mitotic figures (figure 2).
Clinical details, laboratory findings and bone marrow 
morphological features were indicative of congenital 
dyserythropoietic anemia (CDA), type II. Electron 
microscopy and molecular studies were not performed 
due to unavailability at our facility. He was managed 
symptomatically with blood transfusions and iron 
chelation. 
Discussion: CDAs are classically grouped into four 
sub-types based on bone marrow morphological 




Figure1: Peripheral smear showing myelocytes and nucleated red blood 
cells (leucoerythroblastic blood picture)
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A classic histopathology workflow is an 
amalgamation of intricate series of events, including 
a manual review of glass slides that ultimately results 
in diagnosis. An abrupt halt to this smooth running 
occurs when the concerned pathologist finds difficulty 
in judgment, they then consult with colleagues who 
can be in a different lab, city or country altogether. 
Henceforth, the sample needs to be then packaged, 
labeled, and mailed to the intended lab for remote 
consultation. This complete process can be quite 
cumbersome, time demanding because of days/weeks 
lost in transit, and expensive due to the courier costs.
 
The use of digital pathology in education, second-
opinion consultations (real time collaboration), 
slide archiving/retrieval and primary diagnosis has 
grown drastically over the last decade.  By using 
high-throughput, automated digital pathology 
scanners, it is possible to capture an entire glass 
slide, under bright field or fluorescent conditions, 
at a magnification comparable to a microscope 
(Whole slide imaging – WSI). Simulation of virtual 
microscope can be done by its dynamic mode of 
viewing images (horizontal and vertical movement 
of images, and zooming in and out), annotation and 
ability to view the image on a large monitor also 
promotes group interaction and discussion. Images 
can also be accessed anytime with an Internet 
or Intranet connected computer, or other mobile/
portable devices. 
How to get started? Implementation of Digital 
Pathology in Resource Limited setting, Need, 
Challenges and Solutions.
Dr. Sehar Suleman and Dr. Qurratulain Chundriger
Histopathology 
Figure 2: Bone marrow aspirate smear showing dyserythropoietic features, internuclear bridging and nuclear budding.
features. Type I has 
erythroblasts with 
internuclear bridging. 
Type II erythroblasts 
have multinuclearity of 
late erythroblasts while 
type III has gigantoblasts 
(erythroblasts with 
≥8 nuclei), type IV 
causes disturbance in 
transcriptional activator. 
Inheritance is autosomal 
recessive and diagnosis is 
usually made in childhood 
or early adult life. The etiology is not known for all 
the sub-types. The diagnosis of CDA is generally 
considered after other chronic hemolytic anemias 
have been ruled out. Common clinical presentation 
is anemia, jaundice and splenomegaly. Although, 
other more common inherited hemolytic anemias 
have similar presentation, patients with CDA usually 
have high serum ferritin which causes organ damage. 
Bone marrow examination remains a key diagnostic 
tool in identification of the CDAs. CDA type II is 
also called hereditary erythroblastic multinuclearity 
with a positive acidified serum test (HEMPAS), is 
the most common form of CDA and is characterized 
by ineffective erythropoiesis, commonly involved 
mutation is in the SEC23B gene. Treatment is usually 
symptomatic and includes blood transfusions, iron 
chelation therapy and removal of the spleen.
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On the contrary, implementing full scale routine 
digital pathology in low-resource settings remains 
a challenge today. Among the many reasons 
that discourage laboratories from adopting this 
technology include reluctance of many unenthusiastic 
pathologists, to embrace new modality (“Change 
is hard”). Absence of locally made pathology slide 
scanners, digital microscopes or manual whole slide 
image (WSI) softwares (which if available are only 
provided for research work), therefore, the high cost 
of importing equipment, both soft and hard. Limited 
funding/ executive sponsors, lack of high internet 
bandwidth, efficient IT system including internal and 
external network, unreliable electrical power because 
of frequent outages, and adverse weather events which 
could disrupt telecommunications.
Most of the pathologists in our setting have practiced 
telepathology especially during Pandemic lockdown 
by using microscope camera but when it comes to 
the diagnostic utility of these digital images, reliable 
consultation cannot be given due to limitations 
of magnifying details and quality. Since we have 
already gotten comfortable with virtual learning 
these days, it is now, best to gradually start switching 
gears towards digitization. For that matter, liaison 
with world leading biotechnology, bioinformatics 
organizations should be established which could be 
sources of provision of training; they might as well 
offer scanners, digital microscopes and software at a 
relatively negotiable and affordable price, applicable 
for budgets of low resource laboratories. 
Following are the seven steps (Digital Pathology 
System Workflow Road map) that if executed can lead 
an organization to the forefront of Modern Pathology:
1. Getting Laboratory personnel  interested: It is 
important to convince the pathologists and lab 
staff to accept the change, they can be directed 
towards reading up digital pathology related 
articles, studies, best practice recommendations, 
survey barriers/high level needs and understand 
the benefits versus risks based on evidence. At 
this time new visual workflow and feedback can 
be sought after.
2. Defining needs and goals: This requires framing 
a detailed new workflow and business plan, laying 
down how all the steps will be carried out, who 
will carry them out (formulation of teams, roles). 
A checklist can be established as an internal 
quality control for each stage. Concept can also be 
piloted.
3. Specification of infrastructure/ Laboratory 
information system needs:  This step is crucial 
and determines the selection of a project 
technology leader, comparison of various tools, 
budgets (sponsors, aids, expense distribution), 
digital pathology system that is suitable for the 
concerned laboratory and can be integrated 
easily into the LIS. It also includes regulation of 
infrastructure that can accommodate the new 
system, provide storage and security.
4. Building a workflow: This is based on writing 
a statement (standard operating procedure) of 
workflow for each phase of digital conversion 
(image acquisition, preanalytics, image 
management and analysis).
5. Training: Offering of tutorials, training of 
stakeholders, hands on skill training of lab 
personnel is important prior to full adoption 
and to determine gaps and progress. Full 
conversion takes time. After intensive skill 
workshops to cover key essentials, online access 
to complementary materials and manuals can be 
provided.
6. Comparison of both systems and then rollout: 
Pathologists and stakeholders should review the 
glass slides first and then again in coming weeks 
WSI, concordance between the two methods 
should be established and turnaround time should 
be compared, followed by adjustment of digital 
workflow depending on results. After satisfactory 
results, fully convert to digital. Leverage benefits 
at full roll out volume.
7. Analysis and expansion of application: Review 
of speed, volume, and cost improvements, survey 
of customer satisfaction, exploring new insights 
from advanced data analytics, collaboration with 
providers on upgrades and refinement.
Essentials of Digital Pathology System (DPS):
Whole slide imaging systems (WSI) comprise of two 
major components – hardware and software. Typical 
hardware include microscope with lens objectives, light 
source (bright field or fluorescent), robotics to load and 
move glass slides around, digital cameras for image 
capturing and linked computer monitor with a software 
to manipulate, manage and view digital slides.
OCTOBER 2021 VOL 46, ISSUE 4
7
Digital image analysis software development has the 
potential to provide methods for quality assurance in 
slide review and permits quantitative interpretation of 
immunohistochemical staining intensity and location, 
and even image comparisons to archived previously 
diagnosed images. Under the new in vitro diagnostic 
medical device regulation (IVDR) of the European 
Parliament, manufacturers that are currently CE-IVD 
certified are those of Philips, Roche/Ventana, Leica/
Aperio, Hamamatsu, 3DHISTECH.
Before installation of DPS in laboratory, Ergonomics, 
utility and convenience are vital for consideration. 
Recommendations laid down in literature by 
organisations who have completely converted to 
digital include testing out the interface provided 

















operating).  Ability of its integration in lab’s LIS. 
Digital pathology images can be up to several GB in 
size, with higher scan magnification producing larger 
image files. Early communication and interchange 
with IT department is critical, regarding handling of 
image storage (on-premise or in the cloud), as well as 
the network bandwidth, and data security; required 
for such large 
database. 













Figure 1: Whole Slide Imaging 
(Reference: Aperio AT2: Leica biosystems)
Figure 2: A Lean Digital Pathology Clinical Laboratory setting 
(Reference: PANNORAMIC Pathology Management System, 3DHISTECH)
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Peripheral blood smear morphological analysis: 
Morphological evaluation of peripheral blood 
smears by microscopy has a very important role for 
identification of benign and malignant hematological 
disorders. It is also important for picking up 
particular features in non-hematological disorders. 
Detailed morphological analysis includes evaluation 
of red blood cells, white blood cells and platelets. 
Any morphological abnormality is commented on 
complete blood count report and helps clinicians in 
diagnosis.
Over decades, microscopic morphological evaluation 
has been done by trained personnel (hematologists & 
lab scientists), which requires extensive training and is 
time consuming too. Digital morphological evaluation 
of peripheral blood smear is a new beginning in the 
modern era of diagnostics. Several analyzers are now 
available that provide this opportunity of evaluation 
through use of various software.
Principles & methods used in digital morphology: 
Majority of the digital systems use innovative image 
analysis technology based on a prior classification of 
white blood cells (done on the standard counts and 
scatter plot). A similar characterization is present in 
the software for identification of red cells morphology. 
There are approximately 21 morphological features 
described for red blood cells and 17 pre-defined types 
for white blood cells into the system.
Benefits of digital morphological evaluation:
1. Time & labor efficient: Digital evaluation using 
software reduces time for evaluation of multiple 
blood smears. This also helps in reducing the 
workload on hematopathologists. 
2. Inter-observer variance: Pre-defined criteria 
for identification of cells reduces the inter-
observer difference to a large extent.
3. Space constraints: The use of glass slides to 
assess morphology leads to storage and safety 
issues. The use of digital images instead of the 
slides would help in reducing these concerns and 
helps diagnostics to improve.
4. Remote reviews: Digital morphology/images can 
be remotely accessed by professionals improving 
academics and diagnostics.
5. Elimination of eye strain: Another benefit of using 
digital imaging is that, it reduces eye strain 
related to morphological assessment through 
conventional microscopy.
Digital Imaging in Hematology: A New 
Beginning
Dr Hajrah Syndeed, Dr Asif Naveed and Dr Anila Rashid
Haematology & Transfusion Medicine
Figure 1: Digital Morphological Evaluation
(Source of Image: https://www.trademed.com/products/4289/Image-Cap-
ture-System.html)
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6. Education & Training: Digital morphological 
images can be saved into digital library that 
facilitates education on multiple academic levels. 
7. Research: Ease of availability and appropriate use 
of images help for retrospective research for 
various laboratory and clinical disciplines.
Limitation of digital morphology:
1. In neonates and pediatric samples, digital imaging 
may not be helpful for identification of some 
abnormal cells. This will require a routine 
microscopic review (10-20 percent) of total 
samples.
2. Digital morphology has a limited role when it 
comes to identification of malignant cells, 
dysplastic cells, red cell fragmentation, blood 
born parasites and platelet clumps. This may need 
a review from experienced professional.
3. A limited number of standardized soft-wares are 
commercially available and are not very cost 
effective.
Although, digital imaging requires robust validation 
and training of personnel, its introduction has brought 
about a change in modern era of diagnostics allowing 
remote reviews, evaluation of laboratory performance 
through proficiency testing, education and research. 
Vibrational spectroscopies like Fourier transform 
infrared (FTIR) spectroscopy allow classification of 
high-throughput screening of biological specimen 
and equally fits the “omics philosophy” of providing 
unbiased, whole-system measurements. Specifically, 
the use of FTIR spectroscopy to monitor biochemical 
changes in living cells has widely gained importance 
in the last ten years. This technique presents the 
possibility to simultaneously identify various 
cellular biochemical targets, both in vivo and in 
vitro conditions, exploiting the differential infrared 
radiation absorption of each metabolite at a specific 
wave number. 
Molecules and systems of biological relevance that 
can be detected by FTIR spectroscopy include 
molecules such as lipids and fatty acids, proteins, 
peptides, carbohydrates, nucleic acids, and 
biomembranes, animal tissues, microbial cells, plants, 
and clinical samples. However, more recently, it has 
been used, with the aid of sophisticated sampling 
techniques such as infrared imaging, to diagnose 
many diseases such as cervical cancer, Parkinson’s 
disease, Alzheimer’s disease, kidney stone and 
arthritis. So this technique has varied clinical 
application. While literature has reported that this 
technique can be applied for analyzing colon biopsies 
through FTIR spectroscopy and chemometrics in 
identification of colitis and colon cancer. Multiple 
studies have reported that infrared spectra allowed the 
identification of the discriminating molecules, e.g., 
the phosphate content and RNA/DNA ratio which 
can then be used in certain diseases diagnosis and 
monitoring. Cluster analysis of the selected spectra 
provided excellent classifications that correlated 
completely with clinical data. Although these 
results are preliminary, the technique appears to be 
promising, rapid, effective, and economic, assisting in 
the disease diagnosis.
At the Aga Khan clinical laboratory we have been 
identifying the renal and gall stone components using 
the FTIR analysis. FTIR spectroscopy effectively 
provides precise and accurate chemical variation 
information about the structure and the composition 
of the stones.
Fourier-Transform Infrared Spectroscopy; 
Analytical Technique to Detect Metabolites
Dr Muhammad Umer Naeem Effendi 
Clinical Chemistry
OCTOBER 2021 VOL 46, ISSUE 4
10
Fatty acids (FAs) are important and play a significant 
role in health and diseases. The detection of FA 
imbalances, through metabolomics can provide an 
overview of an individual’s health status. These 
disorders are caused by a lack or deficiency of the 
enzymes needed to break down fats, resulting in 
delayed mental and physical development. Children 
with one of these disorders have a deficiency of the 
enzymes needed to break down fats. The lack of one 
of the enzyme leaves the body short of energy and 
accumulate products, such as Acyl-CoA. 
The most common deficiency is medium-chain acyl-
CoA dehydrogenase (MCAD). Other deficiencies 
include short-chain acyl-CoA dehydrogenase (SCAD), 
long-chain 3-hydroxy acyl-CoA dehydrogenase 
(LCHAD) deficiency, very long-chain acyl-CoA 
dehydrogenase (VLCAD) deficiency, glutaric 
acidemia type II etc. can be identified using these 
metabolomics based approaches. Most of these 
disorders begin in infancy. FAO disorders treatment 
varies depending on the type of substances that 
accumulate in the blood.
MCAD deficiency: MCAD is one of the most 
common inherited metabolic disorders. Symptoms of 
the disease usually develop within first few months 
of life. Children are most likely to develop symptoms 
if they go without food for a while or while they have 
increased calories requirement, because of exercise or 
illness. The sugar level significantly decreases in the 
blood (hypoglycemia), causing confusion or coma. 
Children may have vomiting or seizures and become 
weak. Long term symptoms cause delayed mental and 
physical development, liver enlargement, weakness 
of heart muscle with an irregular heartbeat. Sudden 
death may occur. 
LCHAD deficiency: The second most common fatty 
acid oxidation disorder is LCHAD. Symptoms are the 
same as those caused by MCAD. Affected individuals 
may also have progressive impairment of the 
structure, cardiomyopathy, nerve damage, particularly 
the hands and feet, and abnormal liver function. 
When children exert themselves, such as exercising, 
the muscle tissue may become destroyed. The 
damaged muscles may release the protein myoglobin, 
which turns the urine colour brown or bloody.
VLCAD deficiency: VLCAD deficiency is similar 
to LCHAD deficiency but presents with severe 
cardiomyopathy.
Glutaric acidemia type II: Glutaric Acidemia 
type-II is one of the condition termed as organic 
acidemia. Individuals with these conditions have a 
deficiency or absence of an enzyme that prevents the 
breakdown of proteins and fats in the body, resulting 
in several organic acids in the blood and urine. It 
usually appears in infancy or early childhood as a 
sudden episode called a metabolic crisis, in which 
acidosis and hypoglycemia cause weakness, change 
in behaviour such as poor feeding and low activities 
and vomiting. Common childhood illnesses or other 
stresses may trigger these metabolic crises (life-
threatening). 
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The prevalence of gallstones is rising, possibly as a 
result of longer life expectancy and altered nutritional 
habits. Around 9-10.2 percent of Pakistani carry gall 
bladder stones (1). Investigation of the constituents 
of gallstones using spectroscopic procedures helps 
in understanding the pathogenesis and etiology of 
stone formation. In Pakistan, the diagnostic facilities 
for assessing gallstone composition are primitive. 
In the past, gallstone analysis was performed using 
the manual titrimetric and colorimetric technique. 
Not only was this method time and labor intensive, 
but also the results only revealed part of the actual 
composition. Fourier Transform Infra-Red (FTIR) 
Spectroscopy provides a quick and reliable method 
for gallstone analysis. The diamond Attenuated Total 
Reflectance (ATR) accessory allows for detection of 
dry samples without any pre-treatment. It detects light 
absorbance and transmittance in the wavenumber 
range 4,000 to 400 cm-1 (wavelengths 2.5 to 25 µm) 
and produces a unique absorbance pattern for each 
sample. 
The targeted metabolomics study requires an already 
established reference library to match the produced 
absorbance pattern. Unfortunately, no commercially 
available neither a nationally developed library exists 
to match the spectra developed by analyzing gallstone 
samples, rendering the upgradation of gallstone 
analysis impossible. Identifying this resource gap, we 
aimed to develop a Gallstone Standard Library (GSL) 
and a Gallstone Real Patients’ Library (GRPL) and 
validate them using FTIR Spectroscopy in the Section 
of Chemical Pathology, Department of Pathology 
& Laboratory Medicine, Aga Khan University. 
Commercially available pure standards of cholesterol, 
calcium carbonate, bilirubin and bile salts (figure 1) 
as well as gallstone specimens were analyzed using 
FTIR Nicolet iS-5 Spectrometer from Thermo Fisher 
Scientific, USA. Thermo Scientific™ QCheck™ 
algorithm, embedded within the OMNIC™ software, 
was used to identify the unique spectral fingerprint 
of the patient samples to match with known, standard 
material. Similarity of >75 percent was deemed 
adequate. Validation for accuracy of the library was 
achieved for twenty investigated gallstones at an 
international reference lab.
Rigorous examination was executed against the 
established GSL entailing 71 “pure component” 
spectrum separated into five subtypes to generate 
the library. For the GRPL, 117 patient samples from 
various cities of Pakistan were included. Eighty-four 
percent of 117 stones matched with the established 
GSL. Mixed stone was the most common subtype, 
with cholesterol being the primary component. FTIR 
spectrum of pure standards studied of bile salt is 
shown in figure 1. Outcomes of the established library 
were in complete agreement with the results verified 
from the international reference lab. The established 
library exhibited consistency is now effectively used 
for examination of gallstone configuration in our 
population and has replaced the labor- and time-
intensive chemical method of gallstone examination.
Fourier Transform Infrared Spectroscopy – 
Attenuated Total Reflectance (FTIR–ATR) 
based Metabolomics for Gallstones: 
Development of Pakistani Gallstone Library
Drs. Muhammad Abbas Abid and Lena Jafri 
Clinical Chemistry
Figure 1: FTIR spectrum of pure standards studied of bile salt analyzed 
at Section of Chemical Pathology, AKU
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The human leukocyte antigen (HLA) system also 
known as major histocompatibility complex (MHC) 
in humans) is an important component of the 
immune system. It is controlled by genes located 
on chromosome six. The human leukocyte antigen 
(HLA) genes represent the most diverse loci in the 
human genome with over 14,000 alleles identified as 
of December 2015. The high allelic diversity in the 
HLA genes reflects HLA protein function in binding 
and presenting a diverse array of peptide ligands 
derived from microbial pathogens. As a result of 
selection pressure, the HLA system now constitutes 
one of the major genetic differences between 
individuals and among different ethnic populations. 
Therefore, the HLA genes are clinically relevant as 
key determinants of compatibility in organ and bone 
marrow transplantation and genetic susceptibility to 
diseases. However, the highly polymorphic nature 
of HLA genes poses unique challenges for the 
development of molecular approaches to genotype 
HLA alleles. This brief review will summarize the 
utility of next-generation sequencing (NGS) for 
HLA genotyping, highlighting the advantages of this 
approach over other molecular methods for typing 
HLA alleles.
Using standard Sanger sequencing methodology, both 
alleles of a particular HLA locus are amplified and 
sequenced together resulting in multiple heterozygous 
positions in the electropherogram tracing. (Figure 1A).
As the phase of the polymorphic positions cannot be 
visually determined, additional steps are required 
to assign an HLA genotype. These include the 
use of informatics software to query the IMGT/
HLA sequence database and assign the most likely 
combination of alleles, PCR amplification of only one 
allele, or the use of sequencing primers which anneal 
to only one of the two potential HLA alleles. In some 
instances, alternative allele pairs cannot be excluded, 
leading to genotype ambiguity. The additional steps 
required to generate HLA genotypes using Sanger 
sequencing are laborious and time-consuming, thus 
increasing the costs associated with HLA genotyping. 
As a consequence, only a few select exons of an 
entire HLA gene are routinely sequenced in clinical 
laboratories to determine a patient’s HLA genotype 
and ultimately the degree of HLA match between 
donor and recipient.
Next Generation Sequencing: A common feature 
of NGS technologies is that each fragment of DNA 
is amplified and sequenced independently and 
repeatedly, thus reducing the phase ambiguities 
encountered using Sanger sequencing (Figure 1B). 
Several approaches NGS for HLA genotyping have 
been reported using a variety of capture strategies and 
sequencing platforms.
The 454 platform utilized NGS  for HLA genotyping 
for application.  The read length of this technology 
(~ 250-500 bp) was sufficient to cover the average 
size of an HLA exon Similar to Sanger approaches, 
the 454 HLA typing strategies utilized exon-
targeted amplification (Figure 2A), which led to 
challenges in primer design and required numerous 
PCR reactions during library preparation. Although 
automation and microfluidic PCR technology were 
able to mitigate some of these issues, the amplicon-
based sequencing approach was gradually replaced 
by a shotgun sequencing strategy (Figure 2B).  In 
shotgun sequencing approach  long-range PCR is 
used to amplify each HLA locus in a singlereaction. 
PCR amplicons are large and fragmented to produce 
appropriately sized sequencing templates., these 
templets produce the short (100-250 bp) sequencing 
Next-Generation Sequencing for HLA Genotyping
Samina Ghani 
Molecular Pathology
Figure 1: Sanger sequencing methodology
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reads which are aligned to re-create a full-length HLA 
sequence. The advantage of the long-range PCR and 
shotgun sequencing approach is that primers can be 
designed to anneal in less polymorphic regions of the 
HLA genes (5’ and 3’ UTR’s, for example), resulting 
in enhance capture and sequence of the HLA gene 
regions. Paired-end sequencing can also be utilized 
to bioinformatically phase HLA sequence data over 
longer genetic distances (Figure 2C), including regions 
between exons. Multiple commercial assays that utilize 
the shotgun approach for HLA NGS are now available 
for platforms such as Ion Torrent and Illumina.
Finally, bioinformatics approaches have also been 
developed to produce HLA genotyping information 
from targeted capture (exome) and non-targeted 
whole-genome sequence data. One of the major 
hurdle is the lack of sequence coverage from the 
HLA region obtained through exome capture 
techniques and pseudogene leading to misalignment 
of sequence reads. Despite these challenges, 
improved capture strategies and HLA genotyping 
analysis strategies offer the ability to generate 
accurate HLA genotyping from exome and whole-
genome data. Advances in NGS methodologies and 
competitive bioinformatics analysis approaches 
for HLA genotyping, enabled us to define genes 
within the HLA region, identifying polymorphisms 
that may elucidate the evolutionary history of HLA 
alleles, gene expression, and disease risk.
Dysregulated tyrosine kinase (TK) activity is a 
frequent hall- mark of multiple neoplasms. Chronic 
myelogenous leukemia (CML), a myeloproliferative 
disorder, represents a well characterized model 
disease for TK-dependent transformation. On the 
basis of the implementation of basic and clinical 
research into clinical practice, introduction of tyrosine 
kinase inhibitors (TKIs) are now the gold standard 
in the treatment of CML patients and a successful 
example of targeted therapy. The first cases of CML 
in leukemia patients in the late 19th century, were 
diagnosed through an enlarged spleen and markedly 
elevated leukocyte counts. It took almost one century 
to uncover that the Philadelphia chromosome is the 
typical chromosomal change in CML patients and 
another 13 years until Rowley and co-workers showed 
that this anomaly is in fact based on a translocation 
between chromosome 9 and 22. Another ten years 
later, Bartram and co-workers were able to show that 
the tyrosine kinase gene abl on chromosome 9 and the 
bcr gene on chromosome 22 are fused and generate 
the bcr-abl gene on the Philadelphia chromosome. 
The BCR-ABL oncopro-tein is characterized by 
constitutive and increased TK activity and leads to 
malignant transformation of hematopoietic stem and 
progenitors cells resulting in hypercellularity of the 
bone marrow and altered cell adhesion properties of 
leukemic cells both leading to typical leukocytosis 
and sple-nomegaly observed clinically at diagnosis. 
Untreated CML progresses through three distinct 
clinical phases. Initially, CML presents with a 
relatively stable chronic phase (CP) and typically 
develops through an accelerated phase (AP) towards 
myeloid or lymphoid (and rarely megakaryocytic or 
even monocytic) blast crisis (BC), which strongly 
resembles acute leukemia.
ABL Kinase Domain Mutation Analysis by 
Sanger Sequencing for TKI Resistant
Kahkashan Imam, Nazneen Islam, Zeeshan Ansar
Figure 2: Exon-targeted amplification for HLA typing
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Table1: Recommended Testing Parameters for Patients on TKI Therapy per NCCN Guidelines
 Test Recommended Test Specifications 
 Bone marrow Analyze ≥ 20 metaphase cells
     cytogenetics
 FISH Use peripheral blood
  Use dual probes for BCR and ABL1 genes 
 
 RT-qPCR Use an RT-qPCR (IS) assay with sensitivity
      of  ≥ 4.5 log below the standardized baseline  
  Use peripheral blood or bone marrow




At 3 months, if RT-qPCR (IS) is not available 
At 12 months, if neither CCyR nor MMR is achieved 
At 18 months, if no MMR and no CCER at 12 months 
≥1-log increase in BCR-ABL1 level without MMR
At diagnosis, if collection of bone marrow is not feasible Not 
recommended for monitoring response to treatment
At diagnosis
Every 3 months for responding patients
After CCyR is achieved, every 3 months for 3 years, then
   every 3 to 6 months thereafter
If ≥1-log increase in BCR-ABL1 level with MMR, repeat in
   1 to 3 months
If inadequate* response to first-line therapy or any sign
of loss of response, defined as hematologic or cytogenetic 
relapse, or ≥1-log increase in BCR-ABL1 level
and loss of MMR
If disease progression to accelerated or blast phase CML
Clinically Relevant BCR-ABL1 Threshold Levels 
for Predicting TKI Treatment Responses:
The clinical utility of laboratory methods for 
monitoring TKI therapeutic efficacy, including 
hematologic, cytogenetic, and PCR-based techniques, 
depends largely on their limits of detection. Complete 
hematologic response is based on normalization of 
peripheral blood counts [National Comprehensive 
Cancer Network (NCCN) Clinical Practice 
Guidelines in Oncology (NCCN Guidelines) Chronic 
Myelogenous Leukemia Version 3.2013last accessed. 
Cytogenetic response is based on the percentage of 
Ph-positive (Phþ) metaphase cells observed in a bone 
marrow sample, typically by Giemsa staining of 
metaphase chromosome spreads.
Cytogenetic testing does have, however, the capability 
to detect other chromosomal abnormalities besides 
the Ph chromosome, and this may have prognostic 
relevance. Ancillary interphase cell fluorescence 
in situ hybridization (FISH), with DNA probes for 
BCR and ABL1, is also commonly used to monitor 
CML response to treatment. Because 100 to 500 
interphase cells are typically examined with FISH, 
this approach is more sensitive (1:500 to 1:100, or 
0.2 to 1%) than metaphase cytogenetics. Depending 
on the probes used, however, it can have a high 
false-positive rate. FISH lacks practical utility for 
MRD monitoring in the majority of TKI-treated 
CML patients, and therefore is not recommended by 
the NCCN for routine monitoring of TKI treatment 
response (NCCN Guidelines). Instead, guidelines 
from the NCCN, the European Leukemia Net (ELN), 
and the National Institutes of Health recommend 
serial BCR-ABL1 RT-qPCR assays at regular 3- to 
6-month intervals for routine MRD monitoring of 
CML patients receiving TKI therapy. Molecular 
monitoring involves extraction of RNA from a bone 
marrow or peripheral blood specimen and subsequent 
RT-qPCR to measure transcript levels of BCR-ABL1 
relative to those of a reference gene. Because the 
analyte of RT-qPCR, RNA, is labile and degradation 
prone, many pre-analytical variables can affect 
sample quality and quantitative results, including 
sample source (peripheral blood versus bone marrow), 
sample storage (temperature, type of tube), sample 
transport (duration of travel, temperature), and 
sample stabilization (lysis buffer, storage buffer). The 
reference gene in RT-qPCR serves as a control for 
overall RNA quality (with respect to degradation) 
and, assuming equivalent reference gene expression in 
all hematopoietic cells, for the number of input cells 
per PCR reaction. For example, in our laboratory, 
when the level of reference gene RNA falls two 
SD below the mean, RT-qPCR for the BCR-ABL1 
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and reference gene are repeated, and if this repeat 
analysis again shows low reference gene RNA levels, 
the sample is reported as inadequate (new sample 
requested). Compared with cytogenetic testing, PCR-
based molecular monitoring offers exquisite analytical 
sensitivity, 100 to 1000 times greater than FISH or 
bone marrow cytogenetic analysis. It is applicable 
to bone marrow and peripheral blood samples, and 
with a short turnaround time, provides quantitative 
results that are associated with validated clinical 
response thresholds. Disadvantages of RT-qPCR 
include its lack of methodological and reporting 
standardization, its need for specialized laboratories 
and equipment, and the variability of analytical and 
reporting systems. Summarizes current NCCN testing 
recommendations for monitoring TKI treatment 
response in patients with CML.
BCR-ABL1 KD Mutations for Therapeutic Choices
The emergence of BCR-ABL1 KD mutations has 
been shown to be associated with an increased 
likelihood of subsequent disease progression in 
patients with TKI-treated CML, Although the switch 
to an alternative TKI, triggered by the finding of 
a KD mutation, has never been shown to directly 
improve long-term outcomes in a prospective trial, 
ELN and NCCN guidelines nevertheless specifically 
recommend a switch to certain 
TKI agents when particular 
mutations are detected. Due 
to the diversity of mutations, 
full BCR-ABL1 KD mutation 
screening is done in most 
laboratories by a direct Sanger 
DNA sequencing technique 
that has a detection limit of 
approximately 20% mutant 
allele. A significant majority 
of BCR-ABL1 KD mutations 
cluster to one of four hot 
spots: the ATP-binding P-loop 
(amino acids 248 to 256); the imatinib-binding 
region (amino acids 315 to 317); the catalytic domain 
(amino acids 350 to 363); and the activation (A)-loop 
(amino acids 381 to 402).11 Differential sensitivity to 
imatinib, dasatinib, nilotinib, bosutinib, and ponatinib 
has been demonstrated by these diverse mutant 
BCR-ABL1 kinasesin in vitro studies.49e52 Because 
there is often, but not always, a good correlation 
between mutation-specific in vitro resistance and 
in vivo clinical responses for some, but not all, KD 
mutations and TKIs, the identification of the specific 
mutation can help to inform the optimal management 
strategy. In particular, the presence of the common 
T315I mutation suggests that ponatinib, and no 
other TKI, may be effective. In addition, NCCN 
and ELN guidelines suggest a switch to nilotinib 
(not dasatinib) for patients with the V299L, T315A, 
or F317L/V/I/C mutations; and a switch to 
dasatinib (not nilotinib) for patients with the 
Y253H, E255K/V, or F359V/C/I mutations. 
Aside from point mutations, the BCR-ABL1 
KD also commonly develops insertion/
deletion mutations, including a 35-bp intronic 
insertion at the exon 8 to 9 junction, an L248V 
mutation with deletion of 81 bp of exon 4, an 
exon 7 deletion, and several others. Although 
the clinical and drug resistance significance of most 
of these insertion deletion mutations is still unclear, 
the very common 35-bp intronic insertion after exon 
8 does not appear to mediate TKI resistance, in vitro 
or in vivo. The BCR-ABL1 KD also carries some 
common single nucleotide polymorphisms that appear 
to be wholly benign, including three non-synonymous 
(K247R, F311V, Y320C), and three synonymous 
(T240T, T315T, E499E) variants, each of which has no 
known effect on TKI binding or drug resistance.
Figure 1: BCR-ABL1 KD Mutations for Therapeutic Choices
Figure 2: Map of all the amino acid substitutions in the Bcr-Abl KD identified in clinical samples from 
patients reported to be resistant to imatinib
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Organic acids are intermediates of amino acids, 
carbohydrates, lipids and biogenic amine metabolism, 
and any defect in a metabolic pathway may result in 
elevated levels of these metabolites in urine.  The 
scientific study of chemical processes involving 
metabolites is known as metabolomics, so organic 
acid analysis in urine is known as metabolomics 
through organic acid.
At Aga Khan University Hospital, Karachi analysed 
urine organic acid samples by Gas Chromatography-
Mass Spectrometry (GCMS) in Biochemical Genetic 
Laboratory (BGL). A spot-urine sample is required for 
analysis without preservative, and samples are stored 
at -20°C until analysis. The analysis is performed 
using ethyl acetate derived by bis-trimethylsilyl, using 




Figure 3: Interpretation of Bcr-Abl KD identified patient’s samples and Reference sample
Given our evolving 
understanding of the molecular 
events mediating resistance in 
CML and Ph_ ALL, standards 
for reporting of BCR-ABL 
mutational studies would 
benefit from a greater degree 
of uniformity. Commercially-
available reference samples 
and calibrators as well as a 
publicly available BCR-ABL 
mutation database are the 
currently needed resources 
to allow laboratories and 
clinicians to interpret the 
significance of BCR-ABL KD 
mutation studies. While these 
standardization efforts are 
proceeding, mutation studies 
should be based on the already 
developed criteria for clinical 
resistance (summarized above) 
to better ensure appropriate 
utilization. As shared 
databases become more widely 
available, the most appropriate 
statements regarding the 
clinical significance of specific 
mutations will be better 
defined and allow more precise 
guidance to be given.
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Figure 1: A Urine organic acid chromatogram for a Patient with 
Methylmalonic Aciduria
the internal standard 3,3 dimethyl glutaric acid. The 
data generated from the mass detector is analyzed 
by Chemstation software with the help of libraries, 
for example, the NIST library for Organic acids. The 
system’s precision is assessed by analyzing internal 
quality control samples, while for proficiency testing, 
ERNDRIM and CAP samples are analyzed.
One of the most common disorder in Pakistan is 
methylmalonic aciduria which is easily detected 
on GCMS. Methylmalonic acidurias are inherited 
metabolic disorders characterized by elevated 
methylmalonic acid, along with methyl citrate, 
3-hydroxyisovalerate 3-hydroxypropionate, and 
tiglylglycine shown in figure 1. Metabolites are 
widely used as diagnostic and/or prognostic indicators 
of inherited metabolic diseases (IMDs). Urine 
metabolomics plays a key role in diagnosis of these 
disorders.
Next-generation sequencing (NGS) has changed 
the face of oncology research and diagnostics by 
significantly increasing the breadth, sensitivity, and 
specificity of information obtained within a single 
assay. A newer, alternative strategy called next 
generation sequencing (NGS) allows clinicians to 
simultaneous detection of several genes associated 
with cancer. Next generation sequencing can be 
performed on material from a patient’s tumor that has 
been biopsied or surgically removed.
Next-generation sequencing (NGS) is a new 
technology used for DNA and RNA sequencing 
and variant/mutation detection. NGS can sequence 
hundreds and thousands of genes or whole genome in 
a short period of time. Deep sequencing using Next-
generation sequencing (NGS) provides the highly 
sensitive detection of somatic variations in tumor 
subpopulations. Illumina sequencing by synthesis 
(SBS) chemistry is the most widely adopted NGS 
technology.
Next-generation sequencing involves four basic steps:
Library preparation is the first step of next 
generation sequencing. It allows DNA or RNA to 
adhere to the sequencing flow cell and allows the 
sample to be identified. Two common methods of 
library preparation are ligation-based library prep and 
tagmentation-based library preparation.(Figure 1)
Cluster Generation, the library is loaded into a 
flow cell where fragments are captured on a lawn of 
surface-bound oligo complementary to the library 
adapters. Each fragment is then amplified into 
distinct, clonal clusters through bridge amplification 
when cluster generation is complete, the templates are 
ready for sequencing. 
Sequencing Illumina SBS technology uses 
proprietary reversible terminator–based method 
that detects single bases as they are incorporated 
into DNA template strands. As all four reversible 
terminator–bound dNTPs are present during each 
sequencing cycle, natural competition minimizes 
incorporation bias and greatly reduces raw error 
rates compared to other technologies. The result 
is highly accurate base-by-base sequencing that 
Next-Generation Sequencing (NGS) of Solid 
Tumors
Misha Ahmed, Dr Najia Ghanchi 
Molecular Pathology 
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Applications: In section of molecular pathology 
we perform 15 gene hotspot mutation panel that are 
commonly mutated in solid tumors or Commonly 
associated with prognosis of available therapies.. 
Using NGS based testing method, we accurately 
detects variants from small amount of nucleic acid 
extracted from  formalin-fixed, paraffin-embedded 
(FFPE) tumor tissue. Formalin-fixed, paraffin-
virtually eliminates sequence context–specific errors, 
even within repetitive sequence regions and homo 
polymers.
data analysis During data analysis and alignment, 
the newly identified sequence reads are aligned to 
a reference genome. Following alignment, many 
variations of analysis are possible, such as single 
nucleotide polymorphism (SNP)or insertion-deletion 
(indel) identification, read counting for RNA methods, 
phylogenetic or metagenomic analysis, and more.
It provides the sensitivity and accuracy needed to 
identify low-frequency variation with confidence in 
samples of varying quality. High target coverage (at 
least 93.5 percent of bases covered at ≥ 500×) provides 
sensitivity and accuracy required for low-level variant 
calling.
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embedded (FFPE) tissue are routinely used for 
morphological analysis of solid tumors. Both the 
quality and quantity of input DNA are critical for 
producing high-quality data for molecular assays. 
TruSight Tumor 15 assay utilize this method to detect 
15 most commonly mutated genes in seven cancer 
types (Lung,Melanoma, Breast, Colon, Ovarian, 
Gastric, and Prostate).This assay can examine 
multiple cancer-associated genetic alterations 
simultaneously. Solid tumor assay targets genes 
and gene regions include single nucleotide variants 
(SNV) and insertions and deletions (indels) that 
have demonstrated involvement in solid tumors. The 
accurate somatic variant detection of five percent 
allele frequency can be achieved using FFPE tissue 
samples.  Following are the list of genes detected by 
this method AKT1, GNA11, NRAS, EGFR, GNAQ, 
PDGFRA, BRAF, KIT, PIK3CA, FOXL2, KRAS, 
RET, ERBB2, MET, TP53. (Table 1)
Table 1. TruSight Tumor 15 (TST15) Gene Panel Content




GNA11(guanine nucleotide-binding protein 
G protein)
Exon 5*;Q209L Melanoma
NRAS(neuroblastoma RAS viral 





GNAQ (guanine nucleotide binding protein, 
alpha stimulating)
Exon 5*(patient);Q209L Melanoma
PDGFRA  (Platelet Derived Growth 
Factor Receptor Alpha)
Exon 12,14,18 Gastric, Melanoma
EGFR (epidermal growth factor 
receptor)
Focal Amplification, Exons12* 











ERBB2 (erythroblastic oncogene B)
Focal amplification, p.E770_A77insAYVM 
Exon 14 (partial), 17,18,19,20* ,21*(partial) 
,24,26
Lung ,Breast
KRAS ( Kirsten rat sarcoma viral 
oncogene)
Exon2*(partial),3 (partia),4













Lung, Melanoma, Ovary ,Colon
* = Coverage of these exons is only partial and targets 
specific hotspots
The concordance was found 100 percent between 
variants from reference material and TST15 reported 
variants in laboratory our studies. It shows reliable 
variant detection with reported clinical significance. 
It is important to understanding the molecular 
landscape of cancers and contribute to the worldwide 
ongoing effort to determine whether certain variants 
are potentially actionable variants. Next generation 
sequencing method provides concurrent information 
on multiple genes with high quality performance, 
appropriate turnaround times, and optimal use of 
FFPE tissue specimens. With the continuing discovery 
of new cancer biomarkers and availability of robust 
assay clinical services are required to implement more 
comprehensive molecular testing methodologies.
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The transition of “omics” tools utility from 
research to disease diagnosis have revolutionized 
the health care. This paradigm shift in diagnostics 
have opened the new avenues for therapeutic and 
preventive interventions.  Several technologies have 
been employed including transcriptomics, which 
measures mRNA transcript levels; proteomics, which 
quantifies protein abundance; metabolomics, which 
signifies abundance of small cellular metabolites; 
interactomics, which unravels the whole set of 
molecular interactions in cells; and fluxomics, through 
which dynamic changes of molecules within a cell 
are established over time (figure 1). The multi-omics 
approach is required to unravel the difficulties of 
fundamental microbial biology.
Medical microbiology has been transformed by the 
genomics in infectious disease diagnosis, treatment, 
and preventive approaches. Following are few 
exemplary situations in this regard.
1.	 Infectious disease surveillance
In the era of emerging infectious diseases, 
genomic identification of causative agents aids in 
disease burden estimation, epidemiology, trend 
monitoring, and investigation of new outbreaks. 
This has improved public health surveillance 
and also filled the knowledge gaps with-in 
short time span. Studies done in Sub-Saharan 
Africa between 2012 and 2018 found that > 
50 percent newly diagnosed HIV infants are 
resistant to mainstream non-nucleoside reverse 
transcriptase inhibitor (NNRTI) medications. 
This evidence formed the basis of developing 
effective surveillance guidelines and policies. 
World Health Organization (WHO) recently 
updated the recommendation and has included 
HIV integrase region genotype testing (along with 
the reverse-transcriptase and protease regions) in 
all specimens obtained in pretreatment or acquired 
HIV drug resistance.  
WHO supports the use of NGS as an additional 
surveillance tool in below diseases. (figure 2).
2.   Identification of therapeutic targets:
In order to survive, microbes regularly modify 
their structural and functional properties. 
Recognition of these characteristics at 
genomic level brings up opportunities for 
Importance of using Genomic Tool in Microbial 
Identification
Dr. Mohammad Arsalan and Dr. Sobia Khan, 
Microbiology 
Figure 1: Multi-OMICS approach use in disease diagnosis
Figure 2: Pathogen genomics use for disease control programs
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new therapeutic options. In 1998, the genome 
of Mycobacterium tuberculosis H37Rv was 
sequenced, 4000 new potential therapeutic 
targets identified, 50 percent of which were 
given tentative functions. 
Increasing antibiotic resistance and unavailability 
of a viable vaccine candidate has made Neisseria 
gonorrhoeae a “superbug”. A recent study has 
utilized codon biasing, a tool to identify the 
essential genes in N. gonorrhoeae that could be 
utilized as novel therapeutic targets for drug or 
vaccine development. Through the screening 
of 2350 total genes, a list of 29 drug candidate 
genes based on codon adaptation identified. 
Data mining could predict the function of these 
29 genes. These genes are involved in DNA 
replication, energy synthesis and metabolites 
production. A molecule/drug also identified which 
can be used to target essential protein DapD 
(succinyltransferase). 
3.    Antimicrobial resistance:
Antimicrobial resistance (AMR), which is 
currently the most critical public health issue, 
necessitates immediate global effort to counteract 
its negative consequences. According to a recent 
review published on genomics to track global 
AMR, around 47 freely accessible bioinformatics 
resources for detection of AMR determinants 
in DNA or amino acid sequence data have been 
developed. 
WGS for AMR has several advantages over 
traditional methods, as demonstrated by a 
study of emerging aminoglycoside-resistant 
Campylobacter in the United States, where 
sequencing data revealed the rising trend driven 
by nine different resistance alleles, six of which 
had never been detected in Campylobacter 
before and would not have been easily found 
using PCR.
4.    Outbreak control and investigation: 
WGS also links epidemiology and pathogen 
biology, which is critical for determining outbreak 
investigation as it is crucial to determine whether 
an outbreak is caused by natural causes, an 
unintentional release of a cultured or engineered 
organism, or a deliberate introduction of a known 
pathogenic organism. WGS provides significantly 
more resolution than conventional methods 
by producing a complete database of genetic 
polymorphisms (particularly single-nucleotide 
polymorphisms, or SNPs). Methicillin Resistant 
Staphylococcus aureus outbreak in the United 
Kingdom, MLST (multi locus sequence typing) 
identified only one sequence type for a group of 
MRSA isolates, whereas WGS identified several 
distinct clusters.
Two studies of tuberculosis transmission have 
shown that the resolution of WGS with SNP 
typing is much higher than that provided by 
the previous gold standard typing method 
i.e., mycobacterial interspersed repetitive unit 
variable number tandem repeat (MIRU-VNTR) 
typing.
5.    Microbiome:
Meta-omics-based research has revealed 
significant associations between the gut 
microbiome and human diseases such as 
obesity, diabetes, inflammatory bowel disease 
(IBD), cardiovascular disease, and various 
cancers in the last two decades. For instance, 
recent analysis of faecal metagenomic samples 
from patients with colorectal cancer (CRC) 
identified CRC-enriched bacteria, including 
Bacteroides fragilis, Fusobacterium nucleatum, 
Porphyromonas asaccharolytica, Parvimonas 
micra, Prevotella intermedia, Alistipes finegoldii 
and Thermanaerovibrio acidaminovorans, which 
could potentially serve as diagnostic bacterial 
markers across populations.
As a result, omics-based research has opened 
up a whole new world of diagnoses, but it will 
require significant expenditures in Next Generation 
Sequencing, bioinformatics and computer 
infrastructure. Monitoring, evaluation, and 
sustainability frameworks are critical for determining 
the value of NGS over other surveillance techniques, 
identifying gaps and areas for advancement, and 
ensuring that appropriate resources are available for 
its operations.
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Neoplasms that were often included high-grade 
B-cell lymphoma in the past included blastoid or 
pleomorphic variants of mantle cell lymphoma, 
lymphoblastic lymphoma/leukaemia, Burkitt 
lymphoma, high-grade variants of diffuse large 
B-cell lymphoma (DLBCL), and neoplasms 
designated previously in the 2008 World Health 
Organization (WHO) classification as B-cell 
lymphoma,unclassifiable, with features intermediate 
between DLBCL and Burkitt lymphoma.
Aggressive B-cell lymphomas, including diffuse 
large B-cell lymphoma (DLBCL), comprise the most 
commonly diagnosed non-Hodgkin lymphomas in 
the Western world and are potentially curable with 
standard chemoimmunotherapy treatments in up to 
two-thirds of patients.
In the 2016 revision of the WHO classification of 
lymphomas, the term high-grade B-cell lymphoma has 
been repurposed. Most cases in this category include 
so-called double and triple-hit lymphomas falling into 
the subgroup designated high-grade B-cell lymphoma 
with MYC and BCL2 and/or BCL6 rearrangements. 
A smaller subset of cases are designated as high-grade 
B-cell lymphoma, not otherwise specified (NOS). This 
group has overlapping morphological findings with 
double and triple-hit lymphomas, and may carry MYC 
rearrangement in a subset of cases, but lacks double or 
triple-hit genetics as currently defined.
Diagnostic approach for high-grade B-cell 
lymphoma:
The diagnostic approach that can be used in practice. 
When we receive a high-grade B-cell lymphoma, 
blastoid mantle cell lymphoma is excluded with 
cyclin D1, SOX11 immunohistochemistry or FISH 
for IGH-CCND1 translocation. B-lymphoblastic 
leukaemia/lymphoma can be excluded with TdT 
and other immature markers. Of note, a subset of 
high-grade B-cell lymphoma can express TdT so 
it is very important to check other markers such 
as CD34, CD38, BCL6, and monotypic surface 
immunoglobulin. Then, we apply FISH for MYC, 
BCL2 and BCL6. If doublehit or triple-hit is found, 
the case is classified as high-grade Bcell lymphoma 
with MYC and BCL2 and/or BCL6 rearrangements, 
irrespective of morphology. If double-hit or triple-
hit is not found, then the decision depends next 
on morphology. If lymphoma cells are large and 
morphology is typical for DLBCL, then it should 
be classified as such, irrespective of isolated MYC 
rearrangement. If lymphoma cells are intermediate-
size and morphology is typical for BL or intermediate 
between BL and DLBCL, then immunophenotype 
such as BCL2 expression should be checked. If the 
immunophenotype is not typical for BL, then it can be 
classified as high-grade B-cell lymphoma NOS.
Diagnostic Importance of high-grade B-cell 
lymphomas harboring rearrangements of MYC 
and BCL2 and/or BCL6 (HGBL-DH/TH):
According to WHO 2016 classification of lymphoid 
neoplasms, uncommon but clinically significant 
subgroup of high-risk patients with a highly 
aggressive clinical course and dismal long-term 
survival. This subgroup, commonly referred to as 
double hit (DHL) or triple hit lymphoma (THL), 
has been officially classified as “high grade B-cell 
Diagnostic role of c-MYC, BCL2 and BCL6 
rearrangement in B Cell Lymphoma
Sony Siddiqui, Muneba Sharif and Zeeshan Ansar, 
Molecular Pathology 
Figure 1: Algorithm for Diagnostic approach for high-grade B-cell 
lymphoma.
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lymphomas with rearrangements of MYC and BCL2 
and/or BCL6. The standard way to identify these 
aberrations is via fluorescence in situ hybridization 
(FISH) probes. 
MYC expression in DLBCL drives proliferation 
and induces genomic instability. MYC is located on 
chromosome 8 (8q24) and is crucial for metabolism, 
protein synthesis, and amplification of transcription . 
However, BCL2, an oncogene located on chromosome 
18 (18q21), serves to promote cellular survival by 
preventing apoptosis. BCL6 normally encodes a 
transcriptional repressor and when overexpressed, 
can down-regulate several other genes, including 
TP53 (tumor suppressor gene), which subsequently 
allows DNA-damaged cells to escape from apoptosis 
. A typical translocation partner for these genes is the 
immunoglobulin heavy chain gene (IGH) enhancer, 
which is located on chromosome 14 (14q32). The IGH 
enhancers activate efficient and accurate transcription 
of clonal IGH genes. Hence concurrent translocation 
of MYC and BCL2 and/or BCL6 molecularly generates 
a cellular environment of rapid growth countered 
by decreased apoptosis, and leads to a highly 
chemoresistant phenotype.
Figure 1: FISH analysis showing multiple gene rearrangements on paraffin embedded Tissue blocks. Showing (A) BCL2 gene rearrangement, (B) C-Myc 
gene Rearrangement, (C)BCL6 gene Rearrangement (D) MYC/IGH translocation
Triple Hit
The poor prognosis and adverse outcomes following 
standard chemoimmunotherapy for patients 
with aggressive B-cell lymphomas harboring 
dual rearrangements of MYC and BCL2 and/or 
BCL6 is now well-established. Due to the need 
for more intensive induction chemotherapy than 
RCHOP and the potential need to implement CNS 
prophylaxis, it is crucial for treating physicians 
to know whether a patient with newly diagnosed 
DLBCL fits into the HGBL-DH/TH category. In a 
cost-conscious era, routine and widespread testing 
for biologic determinants of outcome may not be 
appropriate, and a critical appraisal of predictors 
is warranted. As a distinct clinical phenotype or 
pathologic morphology cannot be identified to 
accurately predict for underlying HGBL-DH/TH, 
the molecular features of the underlying lymphoma 
are a more objective means to screen for HGBL-
DH/TH. Herein, we have summarized the data to 
support various methods of screening by molecular 
features including COO, protein expression, and 
sequential FISH testing.We recommend screening 
all patient samples with newly diagnosed high-
grade B-cell lymphoma with a dual fusion FISH 
probe for MYC-IGH translocations. If the FISH 
study is positive, the sample can then be tested for 
BCL2/BCL6 translocations. Based on these data, 
this is both the most sensitive and cost-effective 
method to diagnose patients with HGBL-DH/TH 
and to best inform treating physicians to aid in the 
clinical management of these patients.
Double Hit Double Hit
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Launch of e-portal ‘EkSath with patients having 
rare inherited metabolic disorders’ was conducted 
on March 1st, 2021 at the Aga Khan University 
(AKU), Karachi, Pakistan. The event was arranged by 
Department of Pathology and Laboratory Medicine, 
AKU in collaboration with Pakistan Society of 
Chemical Pathologists, and Pak IMD-Net. 
Rare diseases affect many aspects of an individual’s 
life including their social, educational, and 
employment opportunities and are an emerging 
global public health priority. For Pakistani families 
affected by IMDs there is paucity of appropriate 
health services and support groups and it is difficult 
to find and to access information. These opportunities 
are even more limited for families who have a child 
who hasn’t been diagnosed yet. In addition, there 
is a lack of coordination and integration, and no 
central point of access to information on diagnostic 
services, treatment clinics, family support groups or 
up-to-date research. Bearing this in mind, an e-portal 
was developed by Dept. of pathology and laboratory 
Medicine in collaboration with Pak-IMD-Net for 
parents/families with children diagnosed with any 
IMD and physicians involved in the care of IMD 
patients. 
This event was attended by parents/families with 
children diagnosed with any IMD, physicians 
involved in care of IMD patients, and pathologist 
associated with IMD diagnostic laboratories from 
across Pakistan.
Meeting Reports:
Eksath with Patients Having Rare Inherited 
Metabolic Disorders: An E-Portal Launching 
Event  
Drs. Hafsa Majid 
Clinical Chemistry
Picture 1: Picture of the event Organizers and Guest Speakers with the Dean Medical College, Aga Khan University.
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As more molecular diagnostics tests are emerging 
with more sensitive, specific and precise diagnostic 
assays, these methods have assumed a niche in many 
clinical laboratories replacing or complementing the 
existing assays. Hence, it has become imperative to 
strengthen the foundation of molecular pathology 
of our residents by enabling them to be able to 
understand the basic, technical and clinical knowledge 
of the molecular based diagnostic testing. In order to 
achieve this, the PGME committee took an initiative 
by incorporating longitudinal molecular pathology 
course within the existing curriculum.
Post-graduate medical education (PGME) committee 
developed a task force whose aim was to carefully 
design the training program that can be used by 
pathology residency program as a framework that 
caters to enable residents to develop understanding 
of basic concepts of molecular biology along with its 
clinical applications. The committee met monthly 
and worked collaboratively along with representatives 
from different sections and from the year 2021, core 
curriculum for residents was revised to include the 
essential concepts related to molecular pathology. 
As part of the curriculum, we designed a workshop 
on “Basic molecular techniques” for residents of the 
Department of Pathology and Laboratory Medicine.
The workshop comprised of hands-on training, 
interpretation and troubleshooting on techniques 
including Nucleic acid (DNA and RNA) extraction 
using conventional and kit based methods followed by 
conventional and Real-time PCR. The attendees for 
the workshop included in total 14 residents, mostly 
from year III, IV and V along with three residents 
from year I who were able to secure resident research 
grant (RRG) and were supposed to use the basic 
molecular techniques in their projects along with two 
of the residents from clinical hematology who came 
with special request to join the workshop.
The workshop was organized by the faculty from the 
section of Molecular Pathology including Drs. Kiran 
Iqbal and Najia Ghanchi with the help of Pathology 
research staff (Amna Nasir, Sarah Baber and Francis) 
and molecular pathology technologists (Anum Ujala 
and Misha Ahmed). The administrative support was 
provided by Ms. Shamsha Punjwani. The workshop 
was well-appreciated by the attendees. We are happy 
to share some of the snapshots and feedback received:
Basic Molecular techniques (Hands-on) 
workshop for Pathology Residents
Kiran Iqbal Masood
Molecular Pathology
Very interactive and easily defined, need
more hands on like these
Great session learnt basics of molecular
Hands-on experience was very helpful
Overall Great
Hands on was good experience, learnt a
lot, should conduct twice a year
Activity was excellent, highly
recommended for all residents
Everything was perfect at our level
Good workshop, clarified concepts
Need to organize more like these
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History of Artificial intelligence (AI)
The development of “intelligent machines” that can 
mimic human intelligence has always intrigued 
mankind. In Greek mythology, Homer wrote about 
mechanical servants created by Hephaestus to help 
masters. In the 13th century, Al-Jazri designed the 
first robot that worked like a human e.g., playing 
music and washing hands. Artificial intelligence (AI), 
however, is much beyond robotics and involves the 
processing of information and utilization of cognitive 
computing systems. The perception of AI describes it 
as an aiding tool that can improve human quality of 
life and support their need. [i]
In 1956 at the Dartmouth Summer Research 
Project, the field of AI was formally perceived. 
John McCarthy et al. created the term “artificial 
intelligence” and elaborated it as “AI is the science 
and engineering of making intelligent machines, 
especially intelligent computer programs. It is related 
to the similar task of using computers to understand 
human intelligence, but AI does not have to confine 
itself to biologically observable methods ”.[ii] In 
other words, AI representing machines which were 
developed with a wide range of technologies, can 
perform tasks that are representative of human 
intelligence e.g., autonomous vehicle driving. 
AI in Radiology
In 1980, computer-aided diagnosis (CAD) systems 
applied image feature-based analysis and provided 
the radiologist with a “second opinion” i.e., computer 
output to help in final decision making. The two 
examples of CAD utilization were for the detection of 
microcalcification in mammography and pulmonary 
nodules in digital chest radiography. However, in 
cases of discrepancy between the computer reader and 
computer aid, it is important to adopt a more acceptable 
approach for incorporating AI into radiological practice 
by leaving the final judgment to the radiologist. 
In this era of AI, Diagnostic radiology applications 
have witnessed significant progress and growth in 
their workflow. AI not only involves detection of 
pathologies, decision making, and diagnosis but also 
encompasses setting of acquisition parameters, image 
reconstruction, pre-processing along with monitoring 
treatment response and hence patient management. 
The goal of imaging equipment manufacturers is 
to maximize image quality to improve diagnostic 
accuracy. This however comes with increased cost, 
time, and radiation exposure. The post-processing of 
acquired images using AI/machine learning software 
has shown promise in image quality and patient 
throughput. 
Several facilitators and barriers have been 
identified in the implementation of AI in radiology 
practice [iii]. The facilitating factor being “cost 
containment” which is expected to be achieved 
with the development and implementation of 
technological innovations to enhance efficiency 
and quality. The high expectations of the “potential 
added value” of AI are another factor. This includes 
improved diagnostic performance due to automation 
of tasks, and multiple operational benefits like 
reduced workload, consistency in reporting effective 
timesaving, and more advanced service provision. 
The adoption of AI applications also reflects the 
openness towards the adaptation of hospital-wide 
“innovation strategies” of the hospital management 
leadership. The “local champions” i.e., radiologists 
that possess strong knowhow of the technical 
aspects and interest in AI can play an important 
role in the initiations and implementation of AI in 
their department. The strategies to be adopted by 
the local champions to overcome the oppositions 
by their sceptical colleagues are sharing literature 
and presentations for a better understanding of AI 
applications and promoting experimentation by the 
installation of an application test version. This will 
not only convince and familiarize the radiologists 
but also the referring physicians.
Radiology Practice in 21st Century: Role of 
Artificial Intelligence 
Dr Shaista Afzal, Dr Imrana Masroor, 
Radiology
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One of the hindering factors identified in the 
implementation of AI in radiology is the inconsistent 
technical performance of the AI algorithm i.e., the 
sensitivity and specificity. [iv] This was seen with 
the CAD application where a large number of false 
positives created additional work for radiologists 
and the potential of overlooking a lesion. The other 
factors hindering the process of AI application being 
unstructured planning and monitoring, uncertainty 
about the added value in clinical radiology practice 
and workflow and lastly, the trust and acceptance of 
direct and indirect users i.e., radiologists and referring 
physicians.  
Conclusion
AI applications are getting significant attention in 
radiology practice, hence insight into the facilitators 
and barriers in its implementation is crucial. 
Consequently, it is important to include all relevant 
stakeholders during the implementation phases of 
planning, execution, and monitoring. 
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Haematology & Transfusion Medicine
Case presentation:  A 14-month-old boy, presented 
in emergency department with complaints of fever 
and failure to thrive since birth. Physical examination 
revealed pallor and hepatosplenomegaly. Parents had 
non-consanguineous marriage and he was the first 
child. Family history was unremarkable. His complete 
blood count showed: haemoglobin: 8.9 g/dl, white 
blood cells: 4.72 x 10E9/L, absolute neutrophil count: 
0.78 x 10E9/L and platelets: 98 x 10E9/L. Peripheral 
blood smear did not show any atypical cell. Bone 
marrow aspirate and trephine biopsy was performed 
for evaluation of cytopenia which showed cellular 
marrow with trilineage hematopoiesis and active 
hemophagocytosis (histiocytes and macrophages 
engulfing erythroid precursors) [figure 1 and 2]. Other 
laboratory investigations showed low fibrinogen: 93 
mg/dl, high triglycerides: 431 mg/dl and high ferritin: 
85797.5 ng/ml. 
What is the most likely diagnosis?
Hemophagocytic Lymphohistiocytosis (HLH). It is an Figure 1: Bone marrow aspirate showing histiocyte engulfing erythroid and lymphoid precursor
Figure 2: Bone trephine showing histiocyte engulfing erythroid, lymphoid, and myeloid precursor 
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aggressive syndrome of excessive immune activation. 
It is most common in infants and young children but 
can affect patients of any age. These disorders include 
genetic (familial and immunodeficiency-related 
syndromes) and acquired forms. Familial forms are 
autosomal recessive, without a well-defined genetic 
defect rarely mutations in PF1, Munc13-4 (UNC13D) 
and syntaxin 11 (STX11), affecting neonates and 
infant.
Diagnostic criteria: Five of the following nine 
findings:
1.	 Fever ≥ 38.5°C
2.	 Splenomegaly
3.	 Peripheral blood cytopenia, with at least two of 
the following: hemoglobin <9 g/dl (for infants 
<4 weeks, hemoglobin <10 g/dl); platelets 
<100 x 10E9/L; absolute neutrophil count <1 x 
10E9/L
4.	 Hypertriglyceridemia (fasting triglycerides 
>265 mg/dL) and/or hypofibrinogenemia 
(fibrinogen <150 mg/dl) 
5.	 Hemophagocytosis in bone marrow, spleen, 
lymph node, or liver
6.	 Low or absent NK cell activity
7.	 Ferritin >500 ng/ml (ferritin >3000 ng/mL is 
more indicative of HLH) 
8.	 Elevated soluble CD25 (soluble IL-2 receptor 
alpha [sIL-2R]) two standard deviations above 
age-adjusted laboratory-specific norms
9.	 Elevated CXCL9 
Treatment options:  treatment options include 
Corticosteroid: dexamethasone preferred, as it crosses 
blood brain barrier; Immunoglobulin infusions, 
cyclosporine and etoposide; For neurological 
disease: Intrathecal methotrexate with or without 
corticosteroids; Definite treatment is haematopoietic 
stem cell transplantation.
Best of the Recent Past
#Pathologist  #Followtheirlead  
Interviews Recorded by Dr. Qurratulain Chundriger
The world of medicine is changing. With the advent 
of personalized medicine, powered and backed 
by evidence-based practices and more advanced 
diagnostic, predictive and prognostic information, 
the practice of medicine is in the process of a 
metaphorical upside-down flip. This has created 
challenges for pathologists, who need to conform 
their practice to provide more efficient, faster, and 
personalized test results, ultimately translating into 
better care for the patient.
In line with the theme for this Labrad issue, we 
interviewed the section heads of Department of 
Pathology and Laboratory Medicine, to know 
about their vision and foresight in adopting to the 
requirements of the era of modern medicine. However, 
the role each section of our clinical laboratory plays in 
clinical care are too many as well as very diverse, so 
we requested them to focus on two major areas only.
Interviewee: 
Dr. Lena Jafri, 
Associate Professor 






brought to your 
section, and 
how have these 
impacted the 
clinical service provision? 
Advances in the techniques of analytical 
chemistry and metabolomics are the source 
of the rapid evolution of a new omics era. 
The introduction of metabolomics in the 
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Section of Chemical Pathology pertains to two 
important platforms: analytical techniques, (gas 
chromatography mass spectrometry and liquid 
chromatography tandem mass spectrometry) and 
multivariate data analysis software (Collaborative 
Laboratory Integrated Reports -CLIR in 
collaboration with Mayo Clinic, USA). With the 
introduction of mass spectrometers and HPLC 
in the section metabolic profiling of patients 
suspected of having inherited metabolic disorders 
is done. We have screened > 22000 high risk 
children and adults in past 8 years and have 
identified around 40 disorders using these cutting-
edge technologies. 
2.	 And what is your vision for the next five years, 
and how will it benefit patient care? 
I propose three main objectives that will be able to 
configure a rendezvous point and propose future 
directions.  These include:
•	 Predictive medicine: Enhanced sensitivity and 
improved metabolite coverage translating into 
faster and more accurate predictive capacity of 
biomarkers.
•	 Preventive Medicine: Structure across targeted 
metabolomics using mass spectrometry 
supplemented with bioinformatics. This can be 
translated into clinical care through services of 
genetic counselling. 
•	 Collaborations and capacity building: In all three 
disciplines of service, education and research is 
the key to successful utilization of multiomics 
approach for optimal outcomes.
Interviewee: Dr Zeeshan Ansar, Assistant Professor & Section Head Section of 
Molecular Pathology
1.	 What Technological advancements have been 
brought to your section, and how have these 
impacted the clinical service provision? 
Molecular pathology is the rapid advancement 
of technology has been driven by 2 primary 
areas: (1) automated extraction, amplification 
and detection platforms and (2) next-generation 
sequencing. As with any new advanced area, there 
are challenges and limitations that the laboratory 
medicine and public health fields must pay close 
attention to as these developments intersect with 
the care of patients and healthcare and public 
health policy.
2.	 And what is your vision for the next five years, 
and how will it benefit patient care? 
I propose to work in two main areas, including:
Capacity building of my faculty and technologist, 
train them on different genomic, transcriptomic 
based applications. So they are able to conduct 
genomic 
research to 




and are better 
able to grow 
the section in 




Bring in newer 
technologies, broader assays which can detect 
multiple disorders in a single run of a sample, 
introduce services to identify inherited genetic 
diseases, initiate cell free DNA analysis for 
detection of oncology, prenatal screening and 
integrate artificial intelligence into the service to 
improve diagnostics.
OCTOBER 2021 VOL 46, ISSUE 4
30
Interviewee: Dr Arsalan Ahmed, Associate Professor & Section Head Section of 
Histopathology
1.	 What Technological advancements have been 
brought to your section, and how have these 
impacted the clinical service provision? 
The histopathology lab was remodelled in 2019, in 
accordance with the “Lean methodology” in order 
to maximize the productivity in response to the 
continually increasing demands of the workload 
and we have partially gone live with Novopath 
tracking system. The remodelled lab also houses 
“state of the art” grossing hall and a separate 
storage space for blocks and slides for at least 
one year. Along with it, during the past 2 years 
we have brought technological advancements 
by bringing in two 8-color flow cytometer, 
which has helped us to cope with increasing 
volumes, implemented new tests to expand our 
services and by reducing the turnaround time of 
reporting results (within 24 hours). We introduced 
automation in ANA 
(Helios system) and 
Semen Analysis 
(Computer assisted 
sperm analysis). This 





processes , increased 
the capacity of sample size for testing and 
has improved the quality of patient testing by 
maintaining it according to CAP standards. Liquid 
Based Cytology for Pap-smear was introduced 
using BD Sure Path to minimize the risk of 
missing the disease by ensuring that 100% of the 
cells are collected, processed leading to higher 
Interviewee: Dr Imran Ahmed, Assistant Professor & Section Head Section of 
Microbiology
1.	 What Technological advancements have been 
brought to your section, and how have these 
impacted the clinical service provision? 
FilmArray (Biofire) is a real-time multiplex PCR 
technology that integrates sample preparation, 
amplification, detection and analysis. It can 
simultaneously detect 14 and 22 pathogens in CSF 
and nasopharyngeal swab specimens respectively 
in a matter of hours. It reduces turn-around time, 
helps targeted antimicrobial therapy, antimicrobial 
stewardship and thus overall reduction in cost of 
healthcare.
2.	 And what is your vision for the next five years, 
and how will it 
benefit patient 
care? 
My vision is to 
improve diagnostics 
by bringing in 
informatics and 
digitalization in 
Pathology. I plan to 
improve microbial 
identification through introduction of latest 
technology and bringing in laboratory automation 
are the next steps for microbiology.
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Interviewee: Dr Natasha Ali, Associate Professor & Section Head Section of 
Haematology and Transfusion Medicine
1.	 What Technological advancements have been 
brought to your section, and how have these 
impacted the clinical service provision
Introduction of automation in the routine test 
performed in hematology has considerably 
improved the accuracy of results and also the 
efficiency of the laboratory. The automation 
platform performs numerous tests from a single 
EDTA tube. Process improvements such as delta 
checks, pre- and post-analytical sample sorting/
archiving etc. have resulted in smart deliverables 
with much decreased turnaround time leading to 
better patient satisfaction
2.	 And what is your vision for the next five years, 
and how will it benefit patient care?
Innovation in the area of clinical information 
will save laboratory time and labor, while 
enhancing patient care. With improvements in 
optics, electronics, computing algorithms and 
reagent systems – the insights into cellular health 
and physiology also grow. The power of digital 
morphology cannot be underestimated. Digital 
morphologic analysis of haematology specimens 











and do not 
deteriorate 
with time. 
This technique combined with artificial 
intelligence where a software pre-classifies 
and pre-characterizes cells by morphological 
abnormalities using image analysis algorithms, 
opens a new door to the way we interpret and 
diagnose hematological disorders. The future for 
hematology diagnostics is exciting indeed!
detection rate of abnormal cells HSIL (precursor 
for cancer in cervix) and significant reduced 
cases of unsatisfactory samples. It also has the 
option of performing molecular testing on residual 
specimen. 
2.	 And what is your vision for the next five years, 
and how will it benefit patient care? 
In future we plan to introduce Subspecialty 
practice in histopathology, depending 
on the surgical volumes. Improve our 
histopathology workflow processes by 
completely implementing the long-awaited 
tracking system, along with introducing voice 
recognition dictation and going paperless. 
We plan to introduce the Digital pathology 
and Telepathology, expand our services to 
other cities and countries of Middle East and 
Southeast Asia. 
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Polaroid
Picture 1: Integration of urine chemical and microscopic analysis. System perform picture analysis by neural 
network-based algorithm
Picture 2: Technical staff evaluating the graph of Xpert MTB/RIF which detects DNA sequences specific for 
Mycobacterium tuberculosis and Rifampicin resistance by polymerase chain reaction
(Picture is Worth a Thousand Words)
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Picture 3: Haematology resident analyzing hemoglobin variant chromatograph generated by high performance liquid
Picture 4: Haematology residents reviewing bone marrow aspirate smear under microscope.
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Picture 5: Chemical Pathologist interpreting lead spectra analyzed by Atomic absorption mass spectrometry
Picture 6: Chemical Pathologist reviewing the results of plasma Acylcarnitine analyzed by Liquid Chromatography-
Mass Spectrometry
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Picture 7: Technologist analyzing dried blood spot specimen for Acylcarnitine on Liquid Chromatography-Mass 
Spectrometry 
Picture 8: Sequencing cartridge is ready for processing and analysis in Miseq.
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Picture 9: Molecular pathology technologist setting up Next generation sequencing assay for solid tumor testing. 
Picture 10: The Helios HelMed is an automated platform for indirect immunofluorescence studies, which provides AI 
assisted reporting using software and a library of images for structured reporting. In addition, it also suggests the next 
step in testing/diagnosis by recognition of the pattern of positivity.
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Picture 11: AI assisted reporting of Semen DR specimen is crucial for reporting not only the viability and mobility index 
of the spermatozoa but also their speed and structural abnormalities. 
Picture 12: The 8 color BD flowcytometer is the most advanced technology for assessment of antibody panels in 
leukemia/lymphoma diagnosis and calculating minimal residual disease burden to name a few examples.
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Picture 13: Grossing stations fitted with DRAGON speech recognition software, result in quicker turnaround times, 
minimizing the chances of human error at the same time.






Beyond Diagnostics: How To Analyse
Brain MRI Scans for Research?
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Pictures 15-17: A few glimpses of the Research Day of Pathology and Laboratory Medicine.
Polaroid
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hospitals.aku.edu/Karachi/clinical-laboratories
